Diagens Biotechnology Updates IPO Prospectus as Revenue Surges 470% in First Three Quarters
Medical AI firm Diagens Biotechnology is advancing its Hong Kong IPO bid after reporting Q1-Q3 2025 revenue of USD 15.46M, a 470% year-on-year increase, driven by its flagship AI AutoVision® software.
